Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer.

CONCLUSION: The presence of massive lesions (max diameters > 50 mm) is an independent prognostic factor in advanced NSCLC treated with ICI monotherapy. Although overall response rates were similar between groups A and B, the disease control rate was significantly poorer for group A. Max BTS might be useful for predicting clinical outcomes for patients undergoing immunotherapy as a parameter reflecting their tumor burden. PMID: 32462297 [PubMed - indexed for MEDLINE]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research